心通醫療-B(02160.HK):聘任趙亮為集團治療方案推廣高級副總
格隆匯10月5日丨心通醫療-B(02160.HK)宣佈,聘任趙亮為集團治療方案推廣高級副總裁,自2021年10月1日起生效。集團同時整合原銷售和市場部的人才和資源,成立治療方案推广部,由趙亮先生領導,旨在加速推廣集團在結構性心臟病領域創新的經導管及手術治療方案,充分藉助微創醫療科學有限公司及其附屬公司("微創集團")在心臟及心血管疾病治療領域的資源和優勢,在市場準入、運營支持、一線推廣、市場拓展、醫學教育、國際業務等方面充分發揮協同效應,致力於為結構性心臟病患者和醫生提供包括疾病診斷評估、術式和產品宣教、治療方案建議、手術及器械使用培訓、配套器械推薦提供、術中支持,及術後跟蹤隨訪等全解醫療方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.